The Q2 miss and H1 revenue decline are concerning, but the stock's primary driver is the Q4 2026 FDA decision cycle on three BLAs. Monitor for any FDA communication delays or advisory committee meetings. The recent equity raise and term loan provide cash runway through these catalysts. The VAI classification is a positive signal for manufacturing quality.
Price Chart
Executive Summary
Alvotech reported Q2 2026 adjusted EPS of -$0.11, missing consensus of -$0.08 by 30.2%. H1 2026 total adjusted revenue fell 30.8% YoY to $211.9M, driven by a 48.3% decline in product and service revenue due to manufacturing disruptions. The company guided FY2026 revenue to $650-700M and adjusted EBITDA to $180-220M, and has key FDA decisions on three biosimilar BLAs anticipated in Q4 2026, which are the primary catalysts.
Key Financial Metrics
Key Facts
- Q2 2026 adjusted EPS of -$0.11 missed consensus of -$0.08 (-30.2% surprise)
- H1 2026 total adjusted revenue fell 30.8% YoY to $211.9M, with product revenue down 48.3%
- FY2026 guidance: revenue $650-700M, adjusted EBITDA $180-220M
- Cash balance $142.8M at period end, down from $172.4M at Dec 31, 2025
- Raised ~$165M in equity offering and secured $75M term loan from GoldenTree
- FDA decisions on AVT05, AVT06, and AVT03 BLAs expected in Q4 2026
- Manufacturing facility received VAI classification after FDA inspection
Financial Impact
H1 revenue decline of 30.8% YoY; EPS miss of 30.2% vs consensus; FY guidance implies H2 revenue of $438-488M vs H1's $211.9M
Risk Factors
- FDA delays or rejections of AVT05, AVT06, or AVT03 BLAs
- Inability to achieve guided H2 revenue ramp of $438-488M
- Further manufacturing disruptions or quality issues
- Dilution from recent equity offering
- Competitive pressure in biosimilar markets
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3347990 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 6-K | $5.12 | awaiting T+20 | — | $4.75 (−7.23%) |
Oct 14, 2026 13d ago | 6-K | $5.17 | awaiting T+20 | — | $4.75 (−8.12%) |
Oct 7, 2026 20d ago | 6-K | $5.85 | awaiting T+20 | — | $4.75 (−18.80%) |
Oct 5, 2026 22d ago | 6-K | $6.11 | awaiting T+20 | — | $4.75 (−22.26%) |
Oct 5, 2026 22d ago | Press Release | $6.11 | awaiting T+20 | — | $4.75 (−22.26%) |
Aug 31, 2026 8w ago | 6-K | $5.19 $5.92 | ▲ +14.07% | ▲ +14.44% | $4.75 (−8.48%) |
Aug 21, 2026 9w ago | 6-K | $4.43 $5.88 | ▲ +32.73% | ▲ +31.72% | $4.75 (+7.22%) |
Aug 19, 2026 9w ago | Press Release | $4.27 $5.87 | ▼ −37.47% | ▼ −37.59% | $4.75 (−11.24%) |
Jul 29, 2026 12w ago | 6-K | $3.53 $4.91 | ▲ +39.09% | ▲ +34.07% | $4.75 (+34.56%) |
Jul 3, 2026 16w ago | Press Release | $3.46 $4.12 | ▲ +19.08% | ▲ +19.64% | $4.75 (+37.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers